In this study, curdlan sulphate - chitosan nanoparticles were prepared through polyelectrolyte complexing at a mass ratio of 2:1 respectively. The curdlan was produced by fermentation with Agrobacterium sp. ATCC 31750, which was then sulphated to form the polyanionic polymer. A first-line tuberculosis drug, Rifampicin and a phytochemical, DdPinitol, were encapsulated into Curdlan Sulphate (CS) - Chitosan Nanoparticles (C) (CSC NPs) of size 205.41 ± 7.24 nm. The drug release kinetics followed a Weibull model with initial burst release (48 % Rifampicin and 27 % d-Pinitol within 6 h), followed by a sustained release. The prepared CSC: d-PIN + RIF NPs was cytocompatible and entered the M.smegmatis infected macrophages through multiple endocytic pathways including clathrin, caveolae and macropinocytosis. They showed superior bactericidal activity (2.4–2.7 fold) within 4 h when compared to free drug Rifampicin (1.6 fold). The drug encapsulated CSC: RIF suppressed the pro-inflammatory gene (TNF-α by 3.66 ± 0.19 fold) and CSC: d-PIN + RIF increased expression of the anti-inflammatory gene (IL-10 by 13.09 ± 0.47 fold). Expression of TGF- β1 gene also increased when treated with CSC: d-PIN + RIF (13.00 ± 0.19 fold) which provided the immunomodulatory activity of the encapsulated CSC NPs. Thus, curdlan sulphate - chitosan polyelectrolyte complex can be a potential nanocarrier matrix for intracellular delivery of multiple drugs.

在该研究中，通过聚电解质络合分别以2：1的质量比制备了柯德兰硫酸盐-壳聚糖纳米颗粒。通过与土壤杆菌属（Agrobacterium sp。）的发酵来产生凝多糖。然后将ATCC 31750硫酸化以形成聚阴离子聚合物。一线结核病药物利福平和一种植物化学药品D d醇被封装到大小为205.41±7.24 nm的Curdlan Sulphate（CS）-壳聚糖纳米颗粒（C）（CSC NPs）中。药物释放动力学遵循Weibull模型，具有初始爆发释放（在6小时内48％的利福平和27％的d- Pinitol），然后持续释放。制备的CSC：d -PIN + RIF NP具有细胞相容性，并进入了耻垢分枝杆菌通过多种内吞途径（包括网格蛋白，小窝和巨噬细胞）感染巨噬细胞。与游离药物利福平（1.6倍）相比，它们在4小时内显示出优异的杀菌活性（2.4-2.7倍）。封装了CSC：RIF的药物抑制了促炎基因（TNF-α的3.66±0.19倍），而CSC：d -PIN + RIF增加了抗炎基因的表达（IL-10的表达为13.09±0.47倍）。当用CSC处理时，TGF-β1基因的表达也增加：d- PIN + RIF （ 13.00±0.19倍），其提供了包封的CSC NP的免疫调节活性。因此，硫酸柯聚糖-壳聚糖聚电解质复合物可以是用于多种药物的细胞内递送的潜在纳米载体基质。